Alkem Laboratories Ltd
Alkem Laboratories Ltd (ALKEM) last reported results for the quarter ended Jun 2026, with sales of ₹3,740 crore and net profit of ₹521 crore. The stock last traded at ₹5,238, a market capitalisation of ₹62,634 crore, on a P/E of 27.6. Over the past 52 weeks the stock has ranged between ₹5,051 and ₹5,934. Figures are as of 6 Oct 2026 and are not real time.
Alkem Laboratories Ltd share price and key metrics
- Current price
- ₹5,238
- Market cap
- ₹62,634 cr
- Stock P/E
- 27.6
- Book value
- ₹1,156
- ROE
- 18.9%
- ROCE
- 21.2%
- Dividend yield
- 1.02%
- 52w high / low
- 5934/5051
Metrics as of 6 Oct 2026. Not real time.
Track Alkem Laboratories Ltd
Cruxal reads every Alkem Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Alkem Laboratories Ltd growth and returns
- 10 Years
- 12%
- 5 Years
- 11%
- 3 Years
- 8%
- TTM
- 13%
- 10 Years
- 12%
- 5 Years
- 9%
- 3 Years
- 32%
- TTM
- 0%
- 10 Years
- 12%
- 5 Years
- 6%
- 3 Years
- 14%
- 1 Year
- -5%
- 10 Years
- 18%
- 5 Years
- 18%
- 3 Years
- 19%
- Last Year
- 19%
Alkem Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹3,740 cr, up 10.9% from ₹3,371 cr a year earlier. Net profit was ₹521 cr, down 22.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| Expenses | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 | 2,974 |
| Operating profit | 753 | 759 | 391 | 739 | 921 | 828 | 517 | 766 |
| OPM % | 22% | 23% | 12% | 22% | 23% | 22% | 14% | 20% |
| Other income | 134 | 93 | 146 | 149 | 104 | 90 | 65 | 153 |
| Interest | 28 | 36 | 28 | 30 | 35 | 42 | 54 | 47 |
| Depreciation | 79 | 85 | 112 | 88 | 94 | 95 | 106 | 100 |
| Profit before tax | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 |
| Tax % | 10% | 12% | 18% | 13% | 13% | 16% | 40% | 32% |
| Net profit | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 |
| EPS (₹) | 57.60 | 52.34 | 25.58 | 55.56 | 63.99 | 53.19 | 19.78 | 43.49 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Alkem Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,688 | 6,401 | 7,357 | 8,344 | 8,865 | 10,634 | 11,599 | 12,668 | 12,965 | 14,712 | 15,081 |
| Operating profit | 1,001 | 1,009 | 1,120 | 1,476 | 1,945 | 2,054 | 1,622 | 2,249 | 2,512 | 3,007 | 3,032 |
| OPM % | 18% | 16% | 15% | 18% | 22% | 19% | 14% | 18% | 19% | 20% | 20% |
| Net profit | 905 | 638 | 774 | 1,149 | 1,618 | 1,680 | 1,007 | 1,811 | 2,215 | 2,351 | 2,204 |
| EPS (₹) | 74.61 | 52.77 | 63.61 | 94.26 | 132.57 | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 | 180.45 |
TTM is the trailing twelve months to the most recent quarter.
Alkem Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 4,444 | 4,840 | 5,415 | 6,137 | 7,353 | 8,614 | 9,021 | 10,288 | 11,961 | 13,796 |
| Borrowings | 659 | 998 | 944 | 1,616 | 1,707 | 2,668 | 1,397 | 1,418 | 1,381 | 2,047 |
| Other liabilities | 1,440 | 1,803 | 1,824 | 2,169 | 2,435 | 2,763 | 3,315 | 3,844 | 4,325 | 4,991 |
| Total liabilities | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 | 17,691 | 20,858 |
| Fixed assets | 1,797 | 2,284 | 2,530 | 2,908 | 2,793 | 2,902 | 2,683 | 2,873 | 2,852 | 3,871 |
| CWIP | 299 | 381 | 493 | 363 | 393 | 339 | 323 | 159 | 548 | 282 |
| Investments | 553 | 444 | 324 | 261 | 333 | 371 | 622 | 484 | 1,846 | 1,869 |
| Other assets | 3,918 | 4,555 | 4,861 | 6,413 | 8,000 | 10,457 | 10,129 | 12,060 | 12,445 | 14,836 |
| Total assets | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 | 17,691 | 20,858 |
As reported by the company. Total assets equal total liabilities by construction.
Alkem Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 471 | 266 | 780 | 585 | 1,265 | 1,111 | 1,682 | 1,948 | 1,913 | 1,963 |
| Cash from investing | -294 | -351 | -318 | -737 | -995 | -1,433 | 120 | -1,011 | -1,288 | -1,682 |
| Cash from financing | -138 | 85 | -379 | 79 | -272 | 380 | -1,761 | -1,145 | -811 | -503 |
| Net cash flow | 40 | 0 | 82 | -73 | -2 | 58 | 42 | -207 | -186 | -222 |
| Free cash flow | -163 | -411 | 253 | 237 | 1,116 | 783 | 1,453 | 1,761 | 1,278 | 1,476 |
| CFO / operating profit | 73% | 47% | 92% | 59% | 86% | 73% | 121% | 105% | 96% | 86% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Alkem Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 21% | 17% | 16% | 18% | 22% | 18% | 14% | 20% | 20% | 21% |
| Debtor days | 46 | 62 | 62 | 72 | 66 | 65 | 67 | 65 | 69 | 74 |
| Inventory days | 198 | 221 | 186 | 198 | 241 | 262 | 194 | 197 | 224 | 239 |
| Days payable | 122 | 147 | 119 | 104 | 112 | 102 | 87 | 129 | 148 | 161 |
| Cash conversion cycle | 122 | 135 | 129 | 167 | 196 | 225 | 174 | 132 | 145 | 152 |
| Working capital days | 34 | 40 | 55 | 44 | 48 | 31 | 66 | 135 | 123 | 123 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Alkem Laboratories Ltd shareholding pattern
Promoters held 49.70% at Jun 2026, down from 53.04% at Jun 2025. FIIs 10.42% and DIIs 22.64%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 55.66% | 55.66% | 55.13% | 53.04% | 51.20% | 51.20% | 51.20% | 49.70% |
| FIIs | 9.02% | 10.14% | 9.40% | 9.11% | 9.47% | 9.97% | 10.15% | 10.42% |
| DIIs | 19.21% | 18.01% | 19.42% | 21.80% | 21.93% | 21.54% | 21.39% | 22.64% |
| Public | 16.12% | 16.19% | 16.05% | 16.05% | 17.39% | 17.30% | 17.25% | 17.25% |
| No. of shareholders | 74,744 | 84,038 | 84,326 | 79,740 | 67,196 | 64,536 | 62,835 | 62,822 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Alkem Laboratories Ltd corporate filings
- Alkem Laboratories CFO Nitin Agrawal resigns effective September 30, 2026Company Updatelow impact
Cruxal's analysis: Alkem Laboratories Limited has announced the resignation of its Chief Financial Officer…
Read the full analysis - Alkem Laboratories Ltd announces schedule for analyst and institutional investor meetingCompany Updatelow impact
Cruxal's analysis: Alkem Laboratories has issued a formal intimation regarding a scheduled meeting with…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find attached herewith intimation for closure of trading window.
Read the full analysis - Alkem Laboratories Ltd announces issuance of corporate guaranteeCompany Updatelow impact
Cruxal's analysis: Alkem Laboratories has issued a corporate guarantee, a routine financial disclosure under…
Read the full analysis - Alkem Laboratories launches NeuCeno (cenobamate) for adult partial-onset seizuresCompany Updatemedium impact
Cruxal's analysis: Alkem Laboratories has expanded its neurology portfolio with the launch of NeuCeno…
Read the full analysis - Alkem Laboratories appoints Dr. Shubhadeep Sinha as Senior Management PersonnelCompany Updatelow impact
Cruxal's analysis: Alkem Laboratories Limited has announced the appointment of Dr. Shubhadeep Sinha to a…
Read the full analysis - Alkem Laboratories launches Renocia Exo, India's first patented Ginsenoside Exosome-based hair growth serumCompany Updatelow impact
Cruxal's analysis: Alkem Laboratories has expanded its dermatology portfolio with the launch of Renocia Exo…
Read the full analysis - Alkem Laboratories Limited concludes 52nd Annual General Meeting; all resolutions passed by shareholdersAGM/EGMlow impact
Cruxal's analysis: Alkem Laboratories Limited has successfully concluded its 52nd Annual General Meeting…
Read the full analysis - HDFC Mutual Fund increases stake in Alkem Laboratories to 5.017% via open market acquisitionInsider Trading / SASTlow impact
Cruxal's analysis: HDFC Mutual Fund has disclosed an increase in its aggregate shareholding in Alkem…
Read the full analysis - Alkem Laboratories Q1 FY2027 Earnings Call: Revenue Growth of 11% YoY, Margin Pressures from CDMO and Regulatory HeadwindsCompany Updatemedium impact
Cruxal's analysis: Alkem Laboratories reported Q1 FY2027 revenue of INR 3,740 crore, reflecting 11% YoY…
Read the full analysis - Alkem Laboratories shareholders approve amalgamation scheme with Adroit Biomed LimitedAGM/EGMlow impact
Cruxal's analysis: Alkem Laboratories Limited has successfully secured shareholder approval for the scheme…
Read the full analysis - Alkem Laboratories Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Alkem Laboratories has fulfilled its regulatory obligation under Regulation 30 of the…
Read the full analysis - Alkem Laboratories Limited files audio recording of Q1FY2027 earnings conference callCompany Updatelow impact
Cruxal's analysis: Alkem Laboratories Limited has formally submitted the audio recording of its Q1FY2027…
Read the full analysis - The Financials Results of the Company for the quarter ended 30th June, 2026 having been communicated to the Stock Exchanges today ie 14th Aug the trading window shall open on 17th Aug, 2026.Insider Trading / SASTlow impact
- Alkem Laboratories Q1 FY27 Results: Revenue Grows 10.9% YoY, but Net Profit Declines 21.7% Amid Margin PressureCompany Updatehigh impact
Cruxal's analysis: Alkem Laboratories reported Q1 FY27 total revenue from operations of 3,740 crore…
Read the full analysis - Alkem Laboratories Ltd files routine regulatory intimation under Regulation 30Company Updatelow impact
Cruxal's analysis: Alkem Laboratories has submitted a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Alkem Laboratories Q1 FY27 Results: 10.9% Revenue Growth Amidst 21.7% YoY Net Profit DeclineResulthigh impact
Cruxal's analysis: Alkem Laboratories reported Q1 FY27 consolidated revenue of 3,740 crore, reflecting a…
Read the full analysis - Alkem Laboratories Reports Q1 FY27 Consolidated Net Profit of 520.98 crore; Revenue Grows to 3,740.15 croreBoard Meetinghigh impact
Cruxal's analysis: Alkem Laboratories Limited reported consolidated revenue from operations of 3,740.15…
Read the full analysis - Alkem Laboratories provides update on US FDA inspection at Amaliya, Daman facilityCompany Updatelow impact
Cruxal's analysis: Alkem Laboratories has issued a formal intimation regarding the status of a US FDA…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.